NorthCrest Asset Manangement LLC Has $6.34 Million Stock Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

NorthCrest Asset Manangement LLC boosted its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 0.9% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 58,698 shares of the medical equipment provider’s stock after buying an additional 535 shares during the quarter. NorthCrest Asset Manangement LLC’s holdings in Zimmer Biomet were worth $6,336,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. M&G Plc acquired a new position in Zimmer Biomet during the 1st quarter worth $7,397,000. Gradient Investments LLC lifted its stake in shares of Zimmer Biomet by 17.3% in the 2nd quarter. Gradient Investments LLC now owns 130,350 shares of the medical equipment provider’s stock valued at $14,147,000 after purchasing an additional 19,224 shares during the period. CANADA LIFE ASSURANCE Co lifted its stake in shares of Zimmer Biomet by 7.3% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 229,233 shares of the medical equipment provider’s stock valued at $30,265,000 after purchasing an additional 15,548 shares during the period. Swedbank AB acquired a new position in shares of Zimmer Biomet in the 1st quarter valued at $2,740,000. Finally, Forsta AP Fonden lifted its stake in shares of Zimmer Biomet by 95.1% in the 1st quarter. Forsta AP Fonden now owns 99,100 shares of the medical equipment provider’s stock valued at $13,079,000 after purchasing an additional 48,300 shares during the period. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet Trading Down 1.6 %

Shares of NYSE:ZBH opened at $102.35 on Friday. Zimmer Biomet Holdings, Inc. has a 52-week low of $101.47 and a 52-week high of $133.90. The company has a market capitalization of $21.06 billion, a P/E ratio of 22.15, a price-to-earnings-growth ratio of 1.92 and a beta of 1.02. The company has a 50-day simple moving average of $107.61 and a 200 day simple moving average of $111.47. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.63 and a current ratio of 1.29.

Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Wednesday, August 7th. The medical equipment provider reported $2.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.99 by $0.02. The business had revenue of $1.94 billion during the quarter, compared to the consensus estimate of $1.94 billion. Zimmer Biomet had a net margin of 13.25% and a return on equity of 12.86%. Zimmer Biomet’s revenue was up 3.9% on a year-over-year basis. During the same period last year, the business posted $1.82 EPS. Sell-side analysts forecast that Zimmer Biomet Holdings, Inc. will post 7.97 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, October 31st. Shareholders of record on Monday, September 30th will be given a dividend of $0.24 per share. The ex-dividend date of this dividend is Monday, September 30th. This represents a $0.96 annualized dividend and a yield of 0.94%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 20.78%.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the company. Wolfe Research assumed coverage on Zimmer Biomet in a research note on Tuesday, September 10th. They issued a “peer perform” rating on the stock. Needham & Company LLC reaffirmed a “hold” rating on shares of Zimmer Biomet in a research note on Tuesday, September 17th. BTIG Research dropped their price objective on Zimmer Biomet from $134.00 to $126.00 and set a “buy” rating on the stock in a research note on Thursday, October 3rd. Canaccord Genuity Group dropped their price objective on Zimmer Biomet from $120.00 to $115.00 and set a “hold” rating on the stock in a research note on Tuesday, September 10th. Finally, UBS Group lowered their target price on Zimmer Biomet from $112.00 to $107.00 and set a “sell” rating for the company in a report on Thursday, August 8th. Two investment analysts have rated the stock with a sell rating, eleven have given a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $123.94.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.